Neurocompute Narrative Velocity Map
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative
Velocity Map

Explore the Parkinson’s research intelligence diagram before entering the Neurocompute platform.

NC
Neurocompute
AI Parkinson’s Intelligence Terminal
RESEARCH PAPER

HDAC3 blockade inhibits neuroinflammation and pyroptosis to prevent dopaminergic neuron death in Parkinson's disease models.

PMID
41975607
Journal
Neural regeneration research
Publication Date
2026-04-14
Grade
C

AI Summary

In cell and mouse models of Parkinson's disease, HDAC3 inhibition reduced microglial M1 polarization and proinflammatory cytokine production, suppressed pyroptosis via an interaction with HIF‑1α, and preserved nigral dopaminergic neurons with improved behavior.

Why It Matters

Pins HDAC3 as an actionable anti‑inflammatory/anti‑pyroptotic target with in vivo neuroprotection, supporting further preclinical development or repurposing of selective HDAC3 inhibitors for PD therapeutics.

Abstract

Neuroinflammation, mediated by microglial cells, plays a crucial role in the progression of Parkinson's disease. Although the importance of histone deacetylase 3 in neurodegenerative diseases is well recognized, its specific involvement in microglial cells in the context of Parkinson's disease pathogenesis remains unclear. By analyzing gene expression data from the Gene Expression Omnibus database, we identified the potential role of histone deacetylase 3 in Parkinson's disease. We found a significant increase of histone deacetylase 3 in lipopolysaccharide-stimulated BV2 cells and substantia nigra microglial cells of Parkinson's disease model mice. Inhibition of histone deacetylase 3 was found to lead to a notable reduction in the production of proinflammatory factors and promote the transformation of microglial cells from a pro-inflammatory M1 phenotype into an anti-inflammatory M2 phenotype. In addition, histone deacetylase 3 inhibition exerts a neuroprotective effect on co-cultured dopamine neurons in lipopolysaccharide-stimulated BV2 cells. Crucially, the inhibition of histone deacetylase 3 in the in vivo Parkinson's disease model led to enhanced behavioral recovery and halted dopaminergic neuron degeneration in mice. To further investigate the mechanisms underlying this role of histone deacetylase 3, we employed Ingenuity Pathway Analysis software to elucidate the interaction between histone deacetylase 3 and hypoxia-inducible factor 1-alpha. Our study demonstrates that histone deacetylase 3 blockade effectively suppresses the inflammation and M1 polarization of lipopolysaccharide-stimulated microglia. Furthermore, it inhibits pyroptosis through interaction with hypoxia-inducible factor 1-alpha to prevent dopaminergic neuron death. These findings suggest that targeting histone deacetylase 3 could represent a promising therapeutic strategy for Parkinson's disease.

Score Breakdown

AI Score
80.0
Base Score
72.7
Rank Score
69.3
Narrative Velocity
-
AI Confidence
-
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic
Full Neurocompute Infographic